Sanofi, tolebrutinib
Tolebrutinib Slows Disability in Non-Relapsing Secondary Progressive MS
Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's tyrosine kinase (BTK) inhibitor met the study's primary endpoint of delaying time to onset of 6-month confirmed disability progression (CDP),
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi’s Tolebrutinib Delays MS Progression in Phase III Study Following Earlier Flops
The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of back-to-back failures in which tolebrutinib was unable to improve relapse rates in patients with relapsing MS.
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was able to delay the time to six-month disability progression by 31% compared to placebo in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Sanofi says tolebrutinib drug delayed progressive MS by 31%
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in non-relapsing secondary progressive multiple sclerosis.
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
Sanofi’s eyes approval after MS therapy slows disease progression by 31%
After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.
FierceBiotech1d
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
Monthly Prescribing Reference16d
Tolebrutinib Looks Promising for Patients With Non-Relapsing Secondary Progressive MS
Tolebrutinib was found to delay disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), according to results from the HERCULES study.
Benzinga.com18d
Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials
Preliminary analysis of liver safety was consistent with previous tolebrutinib studies. In the HERCULES study, nrSPMS was defined at baseline as having an SPMS diagnosis with an expanded ...
FierceBiotech19d
Sanofi's tolebrutinib fails 2 of trio of phase 3 MS trials, but pharma still plans FDA filing
But, in the GEMINI trials, tolebrutinib failed the primary endpoint of besting Sanofi’s own approved MS drug Aubagio when it came to reducing relapses over up to 36 months. Trying to find the ...
Business Insider19d
Sanofi: Tolebrutinib For NrSPMS Meets Primary Goal In HERCULES Trial; Fails In GEMINI Trial For RMS
(RTTNews) - French drug major Sanofi (SNYNF, SNY) announced Monday that its oral brain-penetrant Bruton's tyrosine kinase or BTK inhibitor Tolebrutinib, in the HERCULES phase 3 study, met the ...